CRISPR moves beyond the laboratory
The approval of Casgevy marked a milestone for genome editing.
In December 2023, the FDA approved Casgevy, marking its first approval of a treatment using CRISPR/Cas9 genome editing technology.
The milestone shows how basic research can reach clinical practice. Approval still applies to specific indications and conditions of use.
Current official documents and product information are available on the FDA page. This article covers the technology and is not a treatment recommendation.
Original sourceFDA